NHO Revive lands Nebraska’s only prostate cancer Phase 3 trial site

NHO Revive is now Nebraska’s only site for a Johnson & Johnson Phase 3 prostate cancer trial testing pasritamig, an investigational immune therapy. The study could expand treatment options for patients whose disease has advanced after standard therapy.

Why it matters: - Nebraska patients now have in-state access to a late-stage prostate cancer study that could open another treatment path after standard options stop working. - The trial tests a therapy designed to redirect T-cells against KLK2, a target found on prostate cancer cells, rather than relying on chemotherapy or hormone-based treatment alone. - The study may help define whether the combination can delay disease progression and improve survival outcomes.

What happened: - NHO Revive became Nebraska’s only site for Johnson & Johnson’s Phase 3 KLK2-PASenger trial. - The trial is testing pasritamig, a novel immune therapy for prostate cancer. - The announcement was dated July 22, 2026. - Dr. Kailash Mosalpura, medical oncologist at Nebraska Hematology-Oncology, said the study brings innovative treatment options directly to patients in Lincoln while helping advance cancer care.

The details: - The study is randomized and open-label. - Researchers are comparing pasritamig plus docetaxel against docetaxel alone. - The primary endpoint is progression-free survival on imaging scans. - Secondary measures include overall survival, quality of life and additional response outcomes. - Eligible patients must have histologically confirmed metastatic prostate adenocarcinoma. - Eligible patients must have disease progression after androgen deprivation therapy and at least one prior novel hormonal therapy. - Participants must be 18 or older. - Participants must have an ECOG performance status of 0 or 1. - Pasritamig is designed to harness the body’s immune system, specifically T-cells, to attack cancer cells that express human kallikrein 2, or KLK2. - NHO Revive is a joint initiative between Nebraska Hematology Oncology and Revive Research Institute. - Nebraska Hematology-Oncology has served Lincoln and surrounding communities since 1997. - Nebraska Hematology-Oncology has seven physicians, 13 advanced practice providers and more than 145 staff. - Nebraska Hematology-Oncology is the first QOPI-certified and Oncology Medical Home APC4-certified clinic in Nebraska. - More information is available in the company’s announcement. - NHO Revive also shared social links for LinkedIn, Instagram and Facebook.

Between the lines: - The trial adds a precision-immunotherapy approach to a disease area where many patients eventually move beyond androgen-directed drugs. - Being the only Nebraska site may make NHO Revive a referral destination for eligible patients across the state. - The combination design suggests Johnson & Johnson wants to learn whether pasritamig can improve on an established chemotherapy backbone.

What’s next: - Eligible patients can be screened for enrollment at NHO Revive. - The trial will continue tracking whether the combination improves disease control, survival and patient-reported outcomes. - Results from the Phase 3 study will help determine whether pasritamig advances further in prostate cancer treatment development.

The bottom line: - Nebraska now has a local entry point into a high-profile Phase 3 prostate cancer immunotherapy trial, and the study could shape future treatment options for advanced disease.